Add Glucokinase Activator to Target A1c

Inclusion Criteria:

- A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes
Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening.

- On a stable (for the last 3 months prior to screening) regimen of metformin
monotherapy equivalent of at least 1000 mg once daily.

- Males, females of childbearing potential (must have a negative pregnancy test and be
willing to comply with protocol contraception), and females of non-childbearing
potential.

- Age 18 to 75 years, inclusive, at the time of screening.

- HbA1c ≥7.0% and ≤9.5%.

- Generally stable health without active infection or history of major surgery or
significant injuries within the last year.

Exclusion Criteria:

- Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young,
insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus,
or history of diabetic ketoacidosis.

- Clinically significant abnormal lab values including eGFR <50ml/min/1.73m2, ALT,
bilirubin or AST >1.5 X ULN, hypokalemia or other clinically significant electrolyte
abnormality.

- History of myocardial infarction, unstable angina, coronary revascularization,
stroke, or transient ischemic attack within 2 years of screening.

- Presence of symptomatic congestive heart failure.

- History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or
devices during the last 2 years or any history of atrial fibrillation or flutter
beyond a single short-term episode (e.g., lasting 1-2 days).

- History or presence of a 2nd degree or greater atrioventricular block in the absence
of a pacemaker.

- A 12-lead ECG, from screening or baseline demonstrating QTcF interval >450 msec for
males or >47 msec for females.

- A family or personal history of long QT syndrome.

- History of pancreatitis.

- Persistent, uncontrolled hypertension.

- Presence of chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic
steatohepatitis [NASH]) and/or known liver cirrhosis.

- Participation in any formal weight loss program, or fluctuation of > 5% in body
weight, or having received medications approved for weight loss within 3 months prior
to screening.

- A positive pre-study drug screen.

- Participation in a clinical trial and receipt of an investigational product within 30
days.

- Have a history of drug abuse within 2 years of screening or a positive pre-screen
drug screen.

- Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice
administered by someone other than the patient within 6 months prior to screening.

- A history of excessive alcohol consumption within the last 2 years prior to screening

- Mental or legal incapacitation.

- Blood donation of approximately 1 pint (500 mL) within 8 weeks.

- History of MEN-2 or family history of medullary thyroid cancer.

- History of cancer, other than non-melanoma skin cancer, that required therapy in the
5 years prior study start.